Inhibikase Therapeutics (IKT) Assets Average (2021 - 2026)
Inhibikase Therapeutics (IKT) has 6 years of Assets Average data on record, last reported at $177.3 million in Q1 2026.
- On a quarterly basis, Assets Average rose 83.81% to $177.3 million in Q1 2026 year-over-year; TTM through Mar 2026 was $177.3 million, a 83.81% increase, with the full-year FY2025 number at $139.9 million, up 147.38% from a year prior.
- Assets Average reached $177.3 million in Q1 2026 per IKT's latest filing, up from $130.4 million in the prior quarter.
- Over the last five years, Assets Average for IKT hit a ceiling of $177.3 million in Q1 2026 and a floor of $6.6 million in Q3 2024.
- A 5-year average of $52.0 million and a median of $31.3 million in 2022 define the central range for Assets Average.
- Peak YoY movement for Assets Average: crashed 67.18% in 2024, then soared 1175.76% in 2025.
- Tracing IKT's Assets Average over 5 years: stood at $26.8 million in 2022, then crashed by 39.48% to $16.2 million in 2023, then surged by 217.95% to $51.5 million in 2024, then skyrocketed by 153.26% to $130.4 million in 2025, then skyrocketed by 35.94% to $177.3 million in 2026.
- Business Quant data shows Assets Average for IKT at $177.3 million in Q1 2026, $130.4 million in Q4 2025, and $84.2 million in Q3 2025.